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Abstract
In the present study, we investigated the effects of heat shock protein 70 (HSP70) on novel object recognition, cell
proliferation, and neuroblast differentiation in the hippocampus. To facilitate penetration into the blood–brain
barrier and neuronal plasma membrane, we created a Tat-HSP70 fusion protein. Eight-week-old mice received
intraperitoneal injections of vehicle (10% glycerol), control-HSP70, or Tat-HSP70 protein once a day for 21 days. To
elucidate the delivery efficiency of HSP70 into the hippocampus, western blot analysis for polyhistidine was
conducted. Polyhistidine protein levels were significantly increased in control-HSP70- and Tat-HSP70-treated groups
compared to the control or vehicle-treated group. However, polyhistidine protein levels were significantly higher in
the Tat-HSP70-treated group compared to that in the control-HSP70-treated group. In addition, immunohistochemical
study for HSP70 showed direct evidences for induction of HSP70 immunoreactivity in the control-HSP70- and Tat-HSP70-
treated groups. Administration of Tat-HSP70 increased the novel object recognition memory compared to untreated
mice or mice treated with the vehicle. In addition, the administration of Tat-HSP70 significantly increased the populations
of proliferating cells and differentiated neuroblasts in the dentate gyrus compared to those in the control or vehicle-
treated group based on the Ki67 and doublecortin (DCX) immunostaining. Furthermore, the phosphorylation of cAMP
response element-binding protein (pCREB) was significantly enhanced in the dentate gyrus of the Tat-HSP70-treated
group compared to that in the control or vehicle-treated group. Western blot study also demonstrated the increases of
DCX and pCREB protein levels in the Tat-HSP70-treated group compared to that in the control or vehicle-treated group.
In contrast, administration of control-HSP70 moderately increased the novel object recognition memory, cell proliferation,
and neuroblast differentiation in the dentate gyrus compared to that in the control or vehicle-treated group. These results
suggest that Tat-HSP70 promoted hippocampal functions by increasing the pCREB in the hippocampus.
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Introduction
Neural stem cells (NSCs) are located in the subventricu-
lar zone of the lateral ventricle and in the subgranular
zone of the dentate gyrus, and differentiate into new
neurons in the olfactory bulb and dentate gyrus [1–3].
These cells are maintained throughout life, and neurogen-
esis in the dentate gyrus is very important because the
hippocampus is the most susceptible region to neurological
disorders including ischemia and Alzheimer’s diseases [4–
7]. In the dentate gyrus, NSCs are located in the subgranu-
lar zone, differentiate into neuroblasts, and then migrate
into the granule cell layer to become mature neurons [2].
Newly generated neurons help the hippocampus to adapt
from new environmental needs and to respond to cognitive
demands, which improves the acquisition of new skills,
movement coordination, and emotional control [8, 9]. The
number of NSCs decreased with age, stress, and chemical
toxins, but can be increased by exercise, environmental en-
richment, and neuropsychiatric drugs such as antidepres-
sants [10–14]. The modification of NSC populations is
critical for neural repair, and NSCs are believed to be a po-
tential therapeutic approach for neurological disorders.
Expression of heat shock protein (HSP) is induced by
abnormal conditions in various cell structures, and HSPs
were named dependent on their molecular weight [15].
HSP70 is a molecular chaperone that is found in the cyto-
sol, nucleus, endoplasmic reticulum, and mitochondria.
HSP70 has diverse functions such as protein folding, pro-
tein translocation across membranes, and non-specific
cytoprotection against various events [16–18]. In the ner-
vous system, HSP70 and its modulators show neuropro-
tective effects against neurological disorders including
Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, and stroke [19–21]. Chronic administration of ex-
ogenous HSP70 improves learning and memory in old
mice, and increases synaptophysin immunoreactivity in
the brain compared to the control group [22]. HSP70 has
a cAMP 26 responsive element (CRE) motif in its pro-
moter region that can be activated by CRE binding protein
(CREB) [23, 24], which is one of the most important path-
ways for long-term memory formation [25, 26]. However,
there has been a lack of evidence on the effects of HSP70
on neurogenesis in the hippocampus.
The blood–brain barrier and plasma membrane are
mostly impermeable to bioactive molecules such as pep-
tides, proteins, and oligonucleotides because of their
unique structures to protect the brain and cells from
toxicants. Conversely, therapeutics with targets located
within the blood-brain barrier and plasma membrane
are usually ineffective [27]. The Tat peptide from the hu-
man immunodeficiency virus-1 (HIV-1) has a short, cat-
ionic, and arginine-rich sequence responsible for its
translocation property [28]. Recently, HIV-1 and its Tat
protein is thought to be one of main factors to impair
cognitive function and adult hippocampal neurogenesis.
Tat inhibits hippocampal neurogenesis in the mouse
brain and significantly reduces the proliferation, migra-
tion, and differentiation of cultured neural precursor
cells [29–31]. However, in a previous study, we demon-
strated that a Tat-fusion protein was efficiently trans-
duced into cells, and demonstrated functional activity
across the blood–brain barrier in the spinal cord [32]
and brain [33]. In addition, Tat-HSP70 showed neuro-
protective effects against ischemic damage in mice [34]
and inhibited inflammatory response induced by ische-
mia [35]. In the present study, we created a Tat-HSP70
fusion protein and observed the effects of Tat-HSP70 on
novel object recognition memory as well as on cell pro-




Forty male C57BL/6 J mice (7 weeks of age) were pur-
chased from Jackson Laboratory Co. Ltd. (Bar Harbor,
ME, USA). Five animals were housed per cage in a con-
ventional area under standard conditions at ambient
temperature (22 ± 2 °C) and humidity (60 ± 5%) on a 12:
12 h light/dark cycle with ad libitum access to food and
water. Animal handling and care conformed to guide-
lines of current international laws and policies (National
Institutes of Health Guide for the Care and Use of La-
boratory Animals, Publication No. 85–23, 1985, revised
1996) and were approved by the Institutional Animal
Care and Use Committee of Seoul National University
(SNU-170807-10). All experiments were conducted with
an effort to minimize the number of animals used and the
physiological stress caused by the procedures employed.
All experimental procedures were conducted according to
ARRIVE guidelines [36].
Construction of expression vectors
A cell-permeable Tat expression vector was prepared in
the present laboratory as previously described [37]. The
cDNA sequence for human HSP70 was amplified by
polymerase chain reaction (PCR) using the following pri-
mer sequences: forward, 5′-CTC GAG ATG GCC AAA
GCC-3′ and reverse, 5′-GGA TCC CTA ATC TAC
CTC CTC-3′. PCR products were excised, eluted (Expin
Gel; GeneAll Biotechnology Co., Ltd., Seoul, Korea), and
ligated into a TA cloning vector (pGEM®-T easy vector;
Promega Corporation, Madison, WI, USA) according to
the manufacturer’s protocol. The purified TA vector
containing human HSP70 cDNA was ligated into the
Tat expression vector to produce a Tat-HSP70 fusion
protein. In a similar fashion, a control HSP70 was con-
structed that expressed the HSP70 protein without Tat.
To produce the Tat-HSP70 and control HSP70 proteins,
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the plasmid was transformed into Escherichia coli BL21
cells. The transformed bacterial cells were grown in 100
mL of lysogeny broth media at 37 °C to a D600 value of
0.5–1.0, and then induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside at 37 °C for 6 h. Harvested cells
were lysed by sonication and purified using a Ni2+-nitri-
lotriacetic acid Sepharose affinity column (Qiagen, Inc.)
and PD-10 column chromatography (GE Healthcare,
Chicago, IL, USA). The purified protein concentrations
were estimated using a Bradford assay [38].
Equal amounts of proteins were analyzed using 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Analyzed proteins were electrotransferred to a polyvinyli-
dene difluoride membrane, and then the membrane was
blocked with tri-buffered saline (25mM Tris-HCl, 140mM
NaCl, 0.1% Tween 20, pH 7.5) containing 5% non-fat dry
milk. The membrane was probed using polyhistidine anti-
bodies (1:2000, His-probe, SantaCruz Biotechnology, Santa
Cruz, CA, USA). Proteins were identified using chemilu-
minescent reagents as recommended by the manufacturer
(Amersham, Franklin Lakes, NJ, USA).
Administration of tat-HSP70
The mice were divided into four groups: control, vehicle
(10% glycerol)-treated, control-HSP70-treated, and Tat-
HSP70-treated group. Vehicle, 5 nmol control-HSP70, or
5 nmol Tat-HSP70 was intraperitoneally administered to
mice at 8 weeks of age, once a day for 3 weeks. This dosage
was adapted because Tat-HSP70 in this dosage showed
neuroprotective effects against Parkinson’s disease induced
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment
in mice [39].
Novel object recognition test
The testing apparatus consisted of an open box (25 cm ×
25 cm × 25 cm) made of black acryl as described in the
previous study [40]. The floor was covered with wood-
chip bedding, which was moved around between trials
and testing days to prevent the build-up of odor in cer-
tain places. The objects to be discriminated were made
of solid metal and could not be displaced by the mice
due to their weight. The objects were cleaned with
bleach to remove residual odors.
On the 20th day of treatment with vehicle, control-
HSP70, or Tat-HSP70, at 1 h after treatment, mice from
each group (n = 10 per group) were allowed to explore
the apparatus for 2 min. On the testing day (21st day of
treatment), two 2-min trials were performed 1 h follow-
ing the last treatment. In the “sample” trial (T1), two
identical objects were placed in two opposite corners of
the apparatus. A mouse was placed in the apparatus and
left to explore these two identical objects. After T1, the
mouse was placed back in its home cage for an inter-
trial interval of 1 h. Subsequently, a “choice” trial (T2)
was performed. In T2, a new object replaced one of the
objects that was present in T1. The mice were exposed
again to two different (familiar and new) objects. Explor-
ation was defined as directing the nose toward the object
at a distance of no more than 2 cm and/or touching the
object with the nose. From this measure, a series of vari-
ables were then calculated: the total time spent in ex-
ploring the two identical objects in T1, and the time
spent in exploring two different objects in T2.
The distinction between familiar and new objects in
T2 was determined by comparing the time spent explor-
ing familiar object with that spent exploring new object.
The discrimination index represents the difference in ex-
ploration time expressed as a proportion of the total
time spent exploring the two objects in T2.
Western blot
Following the novel object recognition test, animals in
the control, vehicle-treated, control-HSP70-treated, and
Tat-HSP70-treated groups (n = 5 in each group) were
sacrificed and analyzed by western blotting as described
previously [32, 40]. Following deep anesthesia with 2 g/kg
urethane (Sigma-Aldrich, St. Louis, MO, USA) and subse-
quent decapitation, the hippocampal tissues were cut into
500-μm-thick sections on a vibratome (Leica Microsystems
GmbH), and the hippocampus was cut out using a surgical
blade. The hippocampal tissues were homogenized in
50 mM phosphate-buffered saline (PBS, pH 7.4) con-
taining 0.1mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (pH 8.0), 0.2% Nonidet P-40,
10mM ethylenediaminetetraacetic acid (pH 8.0), 15mM
sodium pyrophosphate, 100mM β-glycerophosphate, 50
mM sodium fluoride, 150mM sodium chloride, 2 mM so-
dium orthovanadate, 1 mM phenylmethylsulfonyl fluoride,
and 1mM dithiothreitol (DTT). Following centrifugation
for 5min at 16,000×g at 4 °C, the protein concentration
was determined in the supernatants using a Micro BCA
protein assay kit with bovine serum albumin as the stand-
ard (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA,
USA). Aliquots containing 20 μg of total protein were
boiled in loading buffer containing 150mM Tris (pH 6.8),
3 mM DTT, 6% sodium dodecyl sulfate, 0.3% bromophe-
nol blue, and 30% glycerol. Each aliquot was subsequently
loaded onto a polyacrylamide gel. Following electrophor-
esis, the proteins in the gel were transferred to a nitrocel-
lulose membrane (Pall Life Sciences, Port Washington,
NY, USA). To reduce background staining, the membrane
was incubated with 5% non-fat dry milk in PBS containing
0.1% Tween-20 for 45min at 25 °C, which was followed by
incubation with rabbit anti-polyhistidine primary antibody
(1:2000, His-probe, SantaCruz Biotechnology), rabbit
anti-doublecortin (DCX) antibody (1:10,000; Abcam,
Cambridge, UK), rabbit anti-phosphorylated CREB at
Ser133 (pCREB; 1:1000; Cell Signaling Technology,
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Inc., Beverly, MA, USA), or rabbit anti-CREB (1:1000; Cell
Signaling Technology, Inc.), peroxidase-conjugated goat
anti-rabbit IgG (1:5000, SantaCruz Biotechnology), and an
ECL chemiluminescent kit (Pierce; Thermo Fisher Scien-
tific, Inc.).
Tissue processing
Following the novel object recognition test, animals (n =
5 in each group) were deeply anesthetized with 1 g/kg of
urethane (Sigma-Aldrich) and perfused transcardially
with 0.1M PBS (pH 7.4) followed by 4% paraformalde-
hyde in 0.1 M PBS (pH 7.4) as described previously [32,
40]. The brains were dissected and post-fixed for 12 h in
the same fixative. The tissue was cryoprotected by over-
night saturation with 30% sucrose. Serial brain sections
were cut coronally at a thickness of 30 μm using a cryo-
stat (Leica, Wetzlar, Germany), and collected in 6-well
plates containing PBS for further processing.
Immunohistochemistry
All sections were processed under the same conditions
to ensure that the immunohistochemical data were com-
parable among the groups. Tissue sections located at a
distance of 90 μm from each other were selected from
an area between 1.82 and 2.30 mm posterior to the
bregma, as defined by a mouse atlas [41] for Ki67, DCX,
and pCREB immunohistochemistry. The sections were
sequentially treated with 0.3% H2O2 in PBS for 30 min
and 10% normal goat serum in 0.05M PBS for 30 min at
25 °C. Sections first underwent an overnight incubation
with mouse anti-HSP70 antibody (1:500; Calbiochem, EMD
Millipore, Temecula, CA, USA), rabbit anti-Ki67 antibody
(1:1000; Abcam), rabbit anti-DCX (1:5000; Abcam), or
rabbit anti-pCREB (1:400; Cell Signaling Technology, Inc.)
at 25 °C. Thereafter, the sections were treated with biotinyl-
ated goat anti-mouse or anti-rabbit IgG and a streptavidin-
peroxidase complex (1:200; Vector, Burlingame, CA, USA)
for 2 h at 25 °C. Sections were visualized by reaction with 3,
3′-diaminobenzidine tetrachloride (Sigma) in 0.1M Tris-
HCl buffer (pH 7.2) and mounted on gelatin-coated slides.
Sections were dehydrated and mounted with Canada bal-
sam (Kanto Chemical, Tokyo, Japan).
Data analysis
Analysis of the hippocampal dentate gyrus for DCX was
performed using an image analysis system and ImageJ
software v. 1.50 (National Institutes of Health, Bethesda,
MD, USA). Data analysis was carried out under the same
conditions by two observers for each experiment to
ensure objectivity in blinded conditions as described in
the previous study [40]. Tissue sections located at a dis-
tance of 90 μm from each other were selected from an
area between 1.82 and 2.30 mm posterior to the bregma,
as defined by a mouse atlas [41]. Digital images of the
whole dentate gyrus were captured with a BX51 light
microscope (Olympus, Tokyo, Japan) equipped with a
digital camera (DP72, Olympus) connected to a computer
monitor. Images were calibrated into an array of 512 ×
512 pixels corresponding to a tissue area of 1200 μm×
900 μm (100× primary magnification). Each pixel reso-
lution had 256 Gy levels, and the intensity of DCX immu-
noreactivity was evaluated by relative optical density
(ROD), which was obtained after transformation of the
mean gray level using the following formula: ROD= log
(256/mean gray level). The ROD of background staining
was determined in unlabeled portions of the sections
using Photoshop CC 2018 software (Adobe Systems Inc.,
San Jose, CA, USA), and this value was subtracted to cor-
rect for nonspecific staining using ImageJ v. 1.50 software
(National Institutes of Health). Data are expressed as a
percentage of the control group (which was set at 100%).
The Ki67- and pCREB-immunoreactive nuclei in the
whole dentate gyrus was counted using an analysis system
equipped with a computer-based CCD camera (OPTIMAS
software version 6.5; CyberMetrics® Corporation, Phoenix,
AZ, USA; magnification, 100×) as described in a previous
study [42]. The image was converted to a gray-scale image,
and Ki67- and pCREB-immunoreactive nuclei were auto-
matically selected according to the intensity of the immu-
nohistochemical staining for Ki67 and pCREB, respectively.
Statistical analysis
The data were expressed as the mean of the experiments
performed for each experimental investigation. In order
to determine the changes of cell number and ROD, mean
differences among the groups were analyzed statistically by
one-way analyses of variance followed by Bonferroni’s
post-hoc test using GraphPad Prism 5.01 software (Graph-
Pad Software, Inc., La Jolla, CA, USA). The results were
considered to be statistically significant if p < 0.05.
Results
Construction of control-HSP and tat-HSP70 fusion proteins
To produce the control-HSP70 and Tat-HSP70 fusion pro-
teins, human HSP70 genes were fused to a Tat peptide ex-
pression vector, and the control-HSP70 protein was
manufactured without a Tat domain (Fig. 1a). After the
overexpression of vectors, purified control-HSP70 and Tat-
HSP70 fusion proteins were obtained by Nib+-→Ni2+-
nitrilotriacetic acid Sepharose affinity column and PD-10
column chromatography. Western blot analysis revealed
strong bands for control-HSP and Tat-HSP70 (Fig. 1b).
Confirmation of tat-HSP70 delivery into the hippocampus
The delivery of Tat-HSP70 was assessed by western blot
analysis for polyhistidine and by immunohistochemistry
for HSP70. Polyhistidine protein levels were significantly
increased in the hippocampal homogenates of control-
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Fig. 1 Purification and transduction of the Tat-HSP70 protein into the mouse hippocampus. a Overview of the Tat-HSP70 protein. b Expression
and purification of the Tat-HSP70 and control-HSP70 proteins, as assessed by western blot analyses using an anti-polyhistidine antibody. c
Western blot analysis of polyhistidine in the hippocampal homogenates of control, vehicle (10% glycerol)-, control-HSP70-, and Tat-HSP70-treated
groups (n = 5 per group; aP < 0.05, versus control group; bP < 0.05, versus vehicle-treated group; cP < 0.05, versus control-HSP70 treated group). d
Immunohistochemistry for HSP70 in the dentate gyrus of control, vehicle-, control-HSP70-, and Tat-HSP70-treated mice. Note that HSP70
immunoreactive structures are most abundantly found in the Tat-HSP70-treated group. GCL, granule cell layer; ML, molecular layer; PL,
polymorphic layer. Scale bar = 50 μm
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HSP70 and Tat-HSP70-treated group compared to that in
control or vehicle-treated group. In addition, polyhistidine
protein levels were significantly higher in the Tat-HSP70-
treated group compared to that in the control-HSP70-
treated group (Fig. 1c). HSP70 immunoreactivity was faintly
observed in the dentate gyrus of control and vehicle-treated
group, while HSP70 immunoreactivity was abundantly ob-
served in the dentate gyrus of control-HSP70 or Tat-
HSP70-treated group. In addition, HSP70 immunoreactive
structures were more abundant in the dentate gyrus of Tat-
HSP70-treated group compared to that in the control-
HSP70-treated group (Fig. 1d).
Effects of tat-HSP70 on novel object recognition memory
During the training period, there were no significant dif-
ferences on the amount of time spent exploring two
identical objects among the groups. During the testing
period, mice in all groups spent more time exploring the
new object compared with a familiar one. However, mice
in the control-HSP70- and Tat-HSP70-treated groups spent
significantly more time exploring the new object compared
to that in the control or vehicle-treated groups. The
discrimination index was also significantly higher in the
control-HSP70- and Tat-HSP70-treated groups compared
to that in the control or vehicle-treated groups. The dis-
crimination index was significantly higher in the Tat-
HSP70-treated group compared to that in the control-
HSP70-treated group (Fig. 2).
Effects of tat-HSP70 on cell proliferation in the dentate gyrus
In all groups, Ki67-positive nuclei were mainly found in
the subgranular zone of dentate gyrus, but the number
of Ki67-positive nuclei was significantly different among
groups. In the control and vehicle-treated groups, some
Ki67 nuclei was observed in the dentate gyrus (Fig. 3a
and b), and the number of Ki67-positive nuclei was
slightly increased in the vehicle-treated group compared
to that in the control group, although the statistical sig-
nificance was not detected between the control and
vehicle-treated group (Fig. 3e). In the control-HSP70-
and Tat-HSP70-treated groups, Ki67-positive nuclei were
abundant compared to that in the control group (Fig. 3c
and d). The number of Ki67-positive nuclei in the control-
HSP70- and Tat-HSP70-treated groups was significantly
increased by 181.9 and 197.1% of the control group,
respectively (Fig. 3e).
Effects of tat-HSP70 on neuroblast differentiation in the
dentate gyrus
In all groups, DCX immunoreactive neuroblasts were
found in the dentate gyrus. Their cell bodies were lo-
cated in the subgranular zone of dentate gyrus, and their
dendrites extended into the molecular layer of dentate
gyrus. However, DCX immunoreactivity was significantly
different among the groups. In the control and vehicle-
treated groups, DCX-immunoreactive neuroblasts were
found sparsely in the dentate gyrus (Fig. 4a and b), and
the DCX immunoreactivities were similar in the dentate
gyrus between the groups (Fig. 4e). In the control-HSP70-
and Tat-HSP70-treated groups, DCX-immunoreactive
neuroblasts were abundantly found in the dentate gyrus,
and DCX immunoreactivities in the control-HSP70- and
Tat-HSP70-treated groups were significantly increased by
171.5 and 194.2% of the control group, respectively
(Fig. 4c, d, and e). DCX protein levels showed significant
increases in the control-HSP70 and Tat-HSP70-treated
Fig. 2 Exploration time (n = 10 per group; *p < 0.05, significant difference between familiar and novel objects) and discrimination index (n = 10
per group; aP < 0.05, versus control group; bP < 0.05, versus vehicle-treated group; cP < 0.05, versus control-HSP70 treated group) of familiar vs.
novel objects during a novel object recognition test in control, vehicle-, control-HSP70-, and Tat-HSP70-treated mice. Data of the exploration time
for each object (same object, where one object was replaced by a new one on the testing day) are presented as a percentage of total
exploration time. All data are shown as % exploration time ± SEM
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group compared to that in the control group and were
highest in the Tat-HSP70-treated group (Fig. 4f).
Effects of tat-HSP70 on the phosphorylation of CREB in
the dentate gyrus
In all groups, pCREB-immunoreactive nuclei were mainly
found in the subgranular zone of the dentate gyrus. How-
ever, the number of pCREB-immunoreactive nuclei was
significantly different among the groups. A similar pattern
of distribution and the number of pCREB-immunoreactive
nuclei was found in the control and vehicle-treated groups
(Fig. 5a, b, and e). In the control-HSP-treated group,
pCREB-immunoreactive nuclei were abundant compared
to that of the control group, although the statistical
significance was not detected between the control and
control-HSP70-treated groups (Fig. 5c and e). In the Tat-
HSP70-treated group, pCREB-immunoreactive nuclei were
strongly observed in the subgranular zone of the dentate
gyrus, and the number of pCREB-immunoreactive nuclei
was significantly increased in the dentate gyrus by 161.5
and 178.3% of the control group, respectively (Fig. 5d and
e). Western blot study showed the significant in-
creases in pCREB/CREB ratio in the control-HSP70
or Tat-HSP70-treated groups compared to that in the
control or vehicle-treated group. However, there were
no significant differences on the ratio of pCREB/
CREB between control-HSP70 or Tat-HSP70-treated
groups (Fig. 5f).
Discussion
hsp70 can regulate expression via negative feedback [43,
44], and overexpression of HSPA1A suppresses HSP70
induction. Several lines of evidence demonstrate that ex-
ogenous HSP70 can cross the blood–brain barrier and
Fig. 3 Immunohistochemistry for Ki67 in the dentate gyrus of control (a), vehicle- (b), control-HSP70- (c), and Tat-HSP70-treated (d) mice. In all
groups, Ki67-positive nuclei (arrows) are found in the subgranular zone of the dentate gyrus. Note that Ki67-positive nuclei are abundantly
detected in the dentate gyrus of control-HSP70 and Tat-HSP70-treated mice. GCL, granule cell layer; ML, molecular layer; PL, polymorphic layer.
Scale bar = 50 μm. e The number of Ki67-positive nuclei in the dentate gyrus per section for each group are also shown (n = 5 per group; aP <
0.05, versus control group; bP < 0.05, versus vehicle-treated group). Data are presented as mean ± SEM
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protects neurons from damage due to energy deprivation
[45], Alzheimer’s disease [46], and epilepsy [47]. How-
ever, these studies have been conducted in pathological
non-physiological conditions. In the present study, we
made a Tat-HSP70 fusion protein and control-HSP70
protein to deliver HSP70 into neurons, and compared
the effects of control-HSP70 and Tat-HSP70 on novel
object recognition memory as well as cell proliferation
and neuroblast differentiation in the dentate gyrus.
We successfully constructed control-HSP70 and Tat-
HSP70 fusion proteins as indicated by the western blot
analysis for polyhistidine, which showed differences in
expression of polyhistidine at 1.56-kDa according to the
molecular weight of the Tat peptide. To assess the deliv-
ery efficiency of HSP70 into the hippocampus, we
administered control-HSP70 and Tat-HSP70 to mice for
21 days and observed significant increases in the expres-
sion of polyhistidine in both groups compared to that in
the control or vehicle-treated group. However, polyhisti-
dine protein levels were more abundantly found in the
hippocampal homogenates of the Tat-HSP70-treated
group compared to that in the control-HSP70-treated
group. In addition, we also conducted the immunohisto-
chemical staining for HSP70 to elucidate direct transfer
of HSP70 in the hippocampus. Treatment with control-
HSP70 or Tat-HSP70 showed significant increases in
HSP70-immunoreactive structures compared to that in
the control or vehicle-treated group although higher pro-
tein levels of HSP70 were observed in the Tat-HSP70-
treated group than in the control-HSP70-treated group.
Fig. 4 Immunohistochemistry for DCX in the dentate gyrus of control (a), vehicle- (b), control-HSP70- (c), and Tat-HSP70-treated (d) mice. In all
groups, DCX-immunoreactive neuroblasts (arrows) are found in the dentate gyrus with dendrites. Note that DCX-immunoreactive neuroblasts
shows delicate dendritic tree branching in the dentate gyrus of control-HSP70- and Tat-HSP70-treated mice. GCL, granule cell layer; ML, molecular
layer; PL, polymorphic layer. Scale bar = 50 μm. e The relative optical densities (RODs) expressed as a percentage of the value representing the
DCX immunoreactivity in the dentate gyrus of the control group are shown. f Values from western blot analysis is expressed as a ratio of DCX
and β-actin immunoblot band in control group (n = 5 per group; aP < 0.05, versus control group; bP < 0.05, versus vehicle-treated group). Data are
presented as mean ± SEM
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This result suggests that HSP70 protein can cross the
blood–brain barrier in naïve mice, and that Tat-HSP70
was efficiently delivered to the mouse hippocampus.
In the present study, administration of control-HSP70
or Tat-HSP70 for 3 weeks significantly enhanced the
novel object recognition in the mice. This result was
consistent with previous studies showing that exogenous
HSP70 or HSP70 induces improvements in learning and
memory formation [22, 48, 49]. Intranasal administration
of exogenous HSP70 for 5 and 9months resulted in im-
provements in learning and memory in old mice [22]. In
addition, infusion of recombinant HSP70 (hspa1a) into
the dorsal hippocampus facilitates memory consolidation
immediately after training, while administration of HSP70
antibody blocked the memory consolidation immediately
after training [49]. Geranylgeranylacetone, an inducer of
HSP70, enhanced recovery of cognitive/affective function in
the Morris water maze and novel object recognition in a
mouse model of traumatic brain injury [48]. HSP70 has
been found on the external leaflet of neuroblast membranes
and regulate neuroblast migration in the subventricular
zone [50]. Administration of control-HSP70 or Tat-HSP70
for 3 weeks significantly increased cell proliferation and
neuroblast differentiation in the dentate gyrus. However,
administration of geranylgeranylacetone for 8 weeks did not
show any significant changes in DCX-immunoreactive neu-
roblasts in non-stress (control) mice, although they signifi-
cantly increased DCX-immunoreactive neuroblasts in the
stressed mice [51]. In the ischemic animals, Tat-HSP70-
transduced neural precursor cells enhanced the functional
outcome by preventing secondary neuronal degeneration as
well as facilitating neurogenesis with sustained high levels
Fig. 5 Immunohistochemistry for pCREB in the dentate gyrus of control (a), vehicle- (b), control-HSP70- (c), and Tat-HSP70-treated (d) mice. In all
groups, pCREB-positive nuclei (arrows) are mainly observed in the subgranular zone of the dentate gyrus. Note that pCREB-positive nuclei are
strongly observed in the dentate gyrus of Tat-HSP70-treated mice. GCL, granule cell layer; ML, molecular layer; PL, polymorphic layer. Scale bar =
50 μm. e The number of pCREB-positive nuclei per section for each group are shown and f values from western blot analysis is expressed as a
ratio of pCREB and CREB immunoblot band in control group (n = 5 per group; aP < 0.05, versus control group; bP < 0.05, versus vehicle-treated
group). Data are presented as mean ± SEMs
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of growth factors including brain-derived neurotrophic fac-
tor [52]. In an animal model for Alzheimer’s disease, intra-
nasal administration of exogenous HSP70 increases genes
involved in neuronal activity and neurogenesis [53].
To elucidate the possible mechanisms of HSP70 for fa-
cilitating cell proliferation and neuroblast differentiation
in the dentate gyrus, we have focused on the CREB path-
way because activation of CREB is one of the most im-
portant pathways for long-term memory formation and
memory consolidation [25, 26]. Administration of control-
HSP70 or Tat-HSP70 for 3 weeks significantly increased
the number of pCREB-immunoreactive nuclei in the sub-
granular zone of dentate gyrus. This result suggests that
control-HSP70 and Tat-HSP70 facilitated cell proliferation
and neuroblast differentiation in the dentate gyrus by fa-
cilitating the phosphorylation of CREB. CREB is an essen-
tial factor for inducing the formation of synapses, long-
term potentiation, and memory formation in mice [54–
56]. In addition, we also observed that pCREB expression
in the subgranular zone of dentate gyrus was mainly found
in the DCX-immunoreactive neuroblasts in mice [57]. As
CREB is a downstream regulator of the extracellular
signal-regulated kinases (ERK) cascade, direct infusion of
recombinant HSP70 into the dorsal hippocampus en-
hanced ERK activity immediately after training in the
hippocampus of aged mice [49].
Conclusion
Administration of Tat-HSP70 significantly improved novel
object recognition by increasing cell proliferation and
neuroblast differentiation in the dentate gyrus via the en-
hanced phosphorylation of CREB.
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